Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 80

1.

[Outpatient care and disease burden of rheumatoid arthritis : Results of a linkage of claims data and a survey of insured persons].

Albrecht K, Luque Ramos A, Callhoff J, Hoffmann F, Minden K, Zink A.

Z Rheumatol. 2017 Mar 21. doi: 10.1007/s00393-017-0294-4. [Epub ahead of print] German.

PMID:
28324149
2.

Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications.

Ombrello MJ, Arthur VL, Remmers EF, Hinks A, Tachmazidou I, Grom AA, Foell D, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Ilowite NT, Mellins ED, Russo R, Len C, Hilario MO, Oliveira S, Yeung RS, Rosenberg AM, Wedderburn LR, Anton J, Haas JP, Rosen-Wolff A, Minden K, Tenbrock K, Demirkaya E, Cobb J, Baskin E, Signa S, Shuldiner E, Duerr RH, Achkar JP, Kamboh MI, Kaufman KM, Kottyan LC, Pinto D, Scherer SW, Alarcón-Riquelme ME, Docampo E, Estivill X, Gül A; British Society of Pediatric and Adolescent Rheumatology (BSPAR) Study Group, Inception Cohort of Newly Diagnosed Patients with Juvenile Idiopathic Arthritis (ICON-JIA) Study Group, Childhood Arthritis Prospective Study (CAPS) Group, Randomized Placebo Phase Study of Rilonacept in sJIA (RAPPORT) Investigators, Sparks-Childhood Arthritis Response to Medication Study (CHARMS) Group, Biologically Based Outcome Predictors in JIA (BBOP) Group., Langefeld CD, Thompson S, Zeggini E, Kastner DL, Woo P, Thomson W.

Ann Rheum Dis. 2016 Dec 7. pii: annrheumdis-2016-210324. doi: 10.1136/annrheumdis-2016-210324. [Epub ahead of print]

3.

Juvenile arthritis caused by a novel FAMIN (LACC1) mutation in two children with systemic and extended oligoarticular course.

Kallinich T, Thorwarth A, von Stuckrad SL, Rösen-Wolff A, Luksch H, Hundsdoerfer P, Minden K, Krawitz P.

Pediatr Rheumatol Online J. 2016 Nov 24;14(1):63.

4.

Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.

Horneff G, Klein A, Klotsche J, Minden K, Huppertz HI, Weller-Heinemann F, Kuemmerle-Deschner J, Haas JP, Hospach A.

Arthritis Res Ther. 2016 Nov 24;18(1):272.

5.

EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases.

Foster HE, Minden K, Clemente D, Leon L, McDonagh JE, Kamphuis S, Berggren K, van Pelt P, Wouters C, Waite-Jones J, Tattersall R, Wyllie R, Stones SR, Martini A, Constantin T, Schalm S, Fidanci B, Erer B, Dermikaya E, Ozen S, Carmona L.

Ann Rheum Dis. 2016 Apr;76(4):639-646. doi: 10.1136/annrheumdis-2016-210112. Epub 2016 Nov 1.

PMID:
27802961
6.

Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry.

Horneff G, Klein A, Oommen PT, Hospach A, Foeldvari I, Feddersen I, Minden K.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1113-1120. Epub 2016 Sep 8.

PMID:
27749226
7.

Systematic review and critical appraisal of transitional care programmes in rheumatology.

Clemente D, Leon L, Foster H, Minden K, Carmona L.

Semin Arthritis Rheum. 2016 Dec;46(3):372-379. doi: 10.1016/j.semarthrit.2016.06.003. Epub 2016 Jun 9. Review.

PMID:
27496195
8.

[Transition from pediatric to adult rheumatological care].

Minden K, Schalm S.

Z Rheumatol. 2016 Aug;75(6):635-45. doi: 10.1007/s00393-016-0140-0. German.

PMID:
27444620
9.

Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000-2013.

Klotsche J, Raab A, Niewerth M, Sengler C, Ganser G, Kallinich T, Niehues T, Hufnagel M, Thon A, Hospach T, Horneff G, Minden K.

Arthritis Rheumatol. 2016 Dec;68(12):3023-3034. doi: 10.1002/art.39796.

PMID:
27332999
10.

[Standards of care for people with rheumatoid arthritis in Europe : Translation and comments of the eumusc.net recommendations supported by EULAR performed by a national task force of the professional organisations DGRh and VRA supported by "Deutsche Rheumaliga"].

Braun J, Krause A, Aringer M, Burmester G, Bessler F, Engel JM, Faubel U, Fischer-Betz R, Genth E, Gromnica-Ihle E, Hellmich B, Kötter I, Krüger K, Lakomek J, Lorenz HM, Manger B, Märker-Hermann E, Minden K, Müller-Ladner U, Rautenstrauch J, Rehart S, Riemekasten G, Rudwaleit M, Rüther W, Schett G, Schuch F, Schulze-Koops H, Specker C, Wassenberg S, Wiek D, Zink A, Schneider M.

Z Rheumatol. 2016 May;75(4):416-28. doi: 10.1007/s00393-016-0059-5. German.

PMID:
27138788
11.

The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort.

Sengler C, Klotsche J, Niewerth M, Liedmann I, Föll D, Heiligenhaus A, Ganser G, Horneff G, Haas JP, Minden K.

RMD Open. 2015 Dec 8;1(1):e000074. doi: 10.1136/rmdopen-2015-000074. eCollection 2015 Dec 8.

12.

Temporal change in prevalence and complications of uveitis associated with juvenile idiopathic arthritis:data from a cross-sectional analysis of a prospective nationwide study.

Tappeiner C, Klotsche J, Schenck S, Niewerth M, Minden K, Heiligenhaus A.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6):936-44. Epub 2015 Oct 30.

PMID:
26517055
13.

Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics.

Barthel D, Ganser G, Kuester RM, Onken N, Minden K, Girschick HJ, Hospach A, Horneff G.

J Rheumatol. 2015 Nov;42(11):2160-5. doi: 10.3899/jrheum.140472. Epub 2015 Sep 15.

PMID:
26373564
14.

Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database.

Tappeiner C, Schenck S, Niewerth M, Heiligenhaus A, Minden K, Klotsche J.

Arthritis Care Res (Hoboken). 2016 Jan;68(1):46-54. doi: 10.1002/acr.22649.

15.

Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years.

Lovell DJ, Ruperto N, Mouy R, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhaes C, Chavez-Corrales J, Huemer C, Kivitz A, Blanco FJ, Foeldvari I, Hofer M, Huppertz HI, Job Deslandre C, Minden K, Punaro M, Block AJ, Giannini EH, Martini A; Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation..

Arthritis Rheumatol. 2015 Oct;67(10):2759-70. doi: 10.1002/art.39234.

16.

Effect of untreated and treated temporomandibular joint arthritis on mandibular volume development in growing rabbits.

Präger TM, Rafayelyan S, Landau H, Pischon N, Minden K, Jost-Brinkmann PG, Müller-Hartwich R, Mußler A.

J Orofac Orthop. 2015 May;76(3):265-74. doi: 10.1007/s00056-015-0288-2.

PMID:
25929713
17.

Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).

Klotsche J, Niewerth M, Haas JP, Huppertz HI, Zink A, Horneff G, Minden K.

Ann Rheum Dis. 2016 May;75(5):855-61. doi: 10.1136/annrheumdis-annrheumdis-2014-206747. Epub 2015 Apr 29.

PMID:
25926155
18.

Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.

Horneff G, Foeldvari I, Minden K, Trauzeddel R, Kümmerle-Deschner JB, Tenbrock K, Ganser G, Huppertz HI.

Arthritis Rheumatol. 2015 May;67(8):2240-9. doi: 10.1002/art.39145.

19.

Prevalence of overweight in children and adolescents with juvenile idiopathic arthritis.

Schenck S, Niewerth M, Sengler C, Trauzeddel R, Thon A, Minden K, Klotsche J.

Scand J Rheumatol. 2015;44(4):288-95. doi: 10.3109/03009742.2014.999351. Epub 2015 Mar 6.

PMID:
25742802
20.

Uveitis in juvenile idiopathic arthritis.

Heiligenhaus A, Minden K, Föll D, Pleyer U.

Dtsch Arztebl Int. 2015 Feb 6;112(6):92-100, i. doi: 10.3238/arztebl.2015.0092. Review.

Supplemental Content

Loading ...
Support Center